OakChart

Glaukos Corp

GKOSHealthcare·Medical Devices·USA·Large·NYSE·Nov 11 • 9:40 AM ET

239.54+3.35 (1.42%)
2026-11-11 15:41 CET
Market cap
13,981.72 USD m
Revenue, TTM
690.33 USD m
Net income, TTM
-169.80 USD m
Free cash flow, TTM
19.41 USD m
EPS diluted, TTM
-2.94
P/E
-
Compare

Price

GKOS against its 20, 50 and 200-day averages
2050200beatmiss
100.00150.00200.00250.005.4M10.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GKOSclose 239.5420-day 205.0750-day 181.83200-day 145.98239.54

6.1% under 255.19 on 4 Nov 2026. Last 15 sessions, 47.4% high to low

Profile

GKOS
52-week range, 91% of the way up
87.32255.18

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard A. Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

IndexRUT
Employees1094
IPOJun 25, 2015
Beta0.68
ATR, 14d12.22
Rel volume0.33
Short float7.89%
Insider own3.97%
Inst own103.38%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap14.18B
Enterprise Value13.95B
Income-169.80M
Sales690.33M
Book/sh12.12
Cash/sh5.69
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1094
IPOJun 25, 2015

Ratios

P/E-
Forward P/E171.05
PEG-
P/S20.54
P/B19.76
P/C42.11
P/FCF730.55
EV/EBITDA-
EV/Sales20.20
Quick Ratio4.09
Current Ratio4.57
Debt/Eq0.14
LT Debt/Eq0.14
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.94
EPS next Y1.40
EPS next Q0.50
EPS this Y174.95%
EPS next Y107.60%
EPS next 5Y-
EPS past 3/5Y-16.22% -3.95%
Sales past 3/5Y21.51% 17.67%
EPS Y/Y TTM-89.79%
Sales Y/Y TTM46.94%
EPS Q/Q111.67%
Sales Q/Q58.03%
EarningsOct 28 AMC
EPS/Sales Surpr.587.55% 25.58%

Ownership

Insider Own3.97%
Insider Trans-7.50%
Inst Own103.38%
Inst Trans3.87%
ROA-17.16%
ROE-22.84%
ROIC-20.73%
Gross Margin81.13%
Oper. Margin-8.95%
Profit Margin-24.60%
SMA2016.81%
SMA5031.74%
SMA20064.09%
Trades-

Technical

Shs Outstand59.17M
Shs Float56.85M
Short Float7.89%
Short Ratio3.86
Short Interest4.48M
52W High255.18 -6.13%
52W Low87.32 174.33%
Volatility7.18% 5.33%
ATR (14)12.22
RSI (14)67.47
Beta0.68
Rel Volume0.33
Avg Volume1.16M
Volume28,320

Performance

Perf Week-2.90%
Perf Month44.74%
Perf Quarter26.44%
Perf Half Y74.48%
Perf YTD112.15%
Perf Year166.48%
Perf 3Y295.67%
Perf 5Y366.85%
Perf 10Y604.32%
Recom1.27
Target Price242.46
Prev Close236.19
Price239.54
Change %1.42%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 28, 2026InitiatedUUBSNeutral
Jul 06, 2026InitiatedHH.C. WainwrightBuy$168-29.9%
Oct 27, 2025UpgradeWWells FargoEqual Weight → Overweight$120-49.9%
Oct 01, 2025InitiatedGGoldmanBuy$103-57.0%
May 01, 2025DowngradeWWells FargoOverweight → Equal Weight$86-64.1%
Feb 19, 2025UpgradeMMizuhoNeutral → Outperform$140 → $200-16.5%
Dec 11, 2024UpgradeCCitigroupNeutral → Buy$132 → $162-32.4%
Dec 06, 2024InitiatedUUBSBuy$182-24.0%
Dec 02, 2024DowngradeMMorgan StanleyEqual-Weight → Underweight$120-49.9%
Jul 10, 2024DowngradeCCitigroupBuy → Neutral$132-44.9%

Peers

Mkt cap
TickerCompanyMkt cap
SGHTSight Sciences Inc603.58M
ALCAlcon Inc34.34B
BLCOBausch + Lomb Corp7.60B
RXSTRxSight Inc207.59M
STAAStaar Surgical Co1.23B
ABBVAbbvie Inc515.07B
HROWHarrow Inc1.11B
OCULOcular Therapeutix Inc1.46B
LNSRLENSAR Inc58.24M
EYPTEyePoint Inc32.09M

Insider trading

latest 14 of 88
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kliman Gilbert HDirectorNov 04 '26Option Exercise25.772,50064,42539,906Nov 05 07:32 PM
Kliman Gilbert HDirectorNov 04 '26Sale253.002,500632,50037,406Nov 05 07:32 PM
Kliman Gilbert HDirectorNov 04 '26Proposed Sale253.002,500632,500Nov 04 02:31 PM
Navratil TomasCHIEF DEVELOPMENT OFFICEROct 30 '26Option Exercise75.9712,969985,19681,764Nov 03 09:45 PM
Navratil TomasCHIEF DEVELOPMENT OFFICEROct 30 '26Sale238.9744,43610,618,98037,328Nov 03 09:45 PM
Navratil TomasOfficerOct 30 '26Proposed Sale238.9744,43610,618,942Oct 30 01:04 PM
Navratil TomasCHIEF DEVELOPMENT OFFICEROct 05 '26Sale164.451,527251,12069,291Oct 07 07:07 PM
Navratil TomasOfficerOct 05 '26Proposed Sale164.451,527251,121Oct 05 04:08 PM
Navratil TomasCHIEF DEVELOPMENT OFFICERSep 25 '26Sale154.281,615249,15870,818Sep 28 06:23 PM
Navratil TomasOfficerSep 25 '26Proposed Sale154.281,615249,158Sep 25 04:10 PM
Navratil TomasCHIEF DEVELOPMENT OFFICERSep 16 '26Sale166.921,457243,20472,433Sep 18 05:32 PM
Navratil TomasOfficerSep 16 '26Proposed Sale166.921,457243,207Sep 16 04:17 PM
Navratil TomasCHIEF DEVELOPMENT OFFICERAug 28 '26Sale180.6713,7442,483,10473,890Sep 01 06:24 PM
Navratil TomasOfficerAug 28 '26Proposed Sale180.6713,7442,483,098Aug 28 01:41 PM

Held by

AUM
TickerCompanyAUM
IJHiShares Core S&P Mid-Cap ETFAUM: 124.48B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
MDYState Street SPDR S&P MIDCAP 400 ETF TrustAUM: 26.22B
BLCRiShares Large Cap Core Active ETFAUM: 9.73B
SPMDState Street SPDR Portfolio S&P 400TM Mid Cap ETFAUM: 18.90B

News

latest 14 of 206
  • Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
  • Okta Is Joining the S&P 500 as Kenvue Leaves (Barrons.com)
  • Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
  • Why Glaukos Stock Is Surging 30% and Headed for Record Close After Earnings (Barrons.com) +33.65%
  • Glaukos Swings To A Profit As Epioxa Ramps And A $1 Billion 2027 Outlook Raises The Stakes On IDose Coverage Risk (Earnings Whispers)
  • Loading…
  • Glaukos: Q3 Earnings Snapshot (Associated Press)
  • Glaukos Announces Third Quarter 2026 Financial Results (Business Wire)
  • Glaukos Faces Seasonal Test As Epioxa's J-Code Reset Meets A Raised Outlook (Earnings Whispers)
  • Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose TR in Combination with Cataract Surgery (Business Wire)
  • Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases (Business Wire) -6.32%
  • Glaukos Announces Positive Three-Year Epioxa Results Demonstrating Durable Clinical Outcomes in Keratoconus (Business Wire) +6.55%
  • Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 (Business Wire)
  • Glaukos Partners with NBA Champion Stephen Curry to Launch "Could it be KC?" Campaign to Raise Awareness of Keratoconus (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-280.470-0.0960.030211.03168.0412
2026Q22026-07-29-0.140-0.211-0.312185.61150.9313
2026Q12026-04-29-0.180-0.281-0.341150.5713713
2025Q42026-02-17-0.280-0.196-2.324143.12136.415
2025Q32025-10-29-0.160-0.261-0.283133.54122.4415
2025Q22025-07-30-0.240-0.264-0.344124.12115.5215
2025Q12025-04-30-0.220-0.348-0.320106.66102.4815
2024Q42025-02-20-0.400-0.383-0.604105.5100.7515
2024Q32024-11-04-0.280-0.478-0.38996.6791.5012
2024Q22024-07-31-0.520-0.515-0.99795.6988.8613
2024Q12024-05-01-0.700-0.577-0.82485.6279.6012
2023Q42024-02-21-0.630-0.549-0.75382.3781.0013
2023Q32023-11-01-0.500-0.550-0.62578.0575.2512
2023Q22023-08-02-0.550-0.555-0.68080.4074.7312
2023Q12023-05-03-0.590-0.575-0.72373.9067.5912
2022Q42023-02-22-0.530-0.546-0.65971.2368.0712

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.100-0.7240.375236.98234.05
2020FY-1.150-1.499-2.705224.96220
2021FY-0.830-0.879-1.068294.01288.16
2022FY-2.180-2.200-2.091282.86279.63
2023FY-2.270-2.220-2.780314.71313
2024FY-1.860-1.830-2.775383.48378.74
2025FY-0.900-0.823-3.280507.44500.21
2026FY-0.675--780.53
2027FY-1.400--1,003
2028FY-2.408--1,295
2029FY-3.960--1,604
2030FY-5.350--1,818

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-2914140233.33231.9236
2026Q4S2026-10-281420187.47180192.98
2026Q4S2026-10-161420187.47180192.98
2026Q4S2026-10-131420187.48180192.98
2026Q4S2026-10-1214140187.48180192.98
2026Q4S2026-10-0914140187.48180193
2026Q4S2026-10-0814140187.48180193
2026Q4S2026-10-0614140187.47180193
2026Q4S2026-10-0514140186.97180191.1
2026Q4S2026-09-2914140186.97180191.1
2026Q4S2026-09-1814140186.98180191.1
2026Q4S2026-09-0214140186.8180191.1
2026Q4S2026-08-1914140186.8180191.1
2026Q4S2026-08-1314140186.8180191.1

Estimate history

EPS, annual-0.003-0.3670.375-2.705-1.068-2.091-2.78-2.775-3.282-2.9447
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.389-0.604-0.32-0.344-0.283-2.324-0.341-0.3120.033
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual159.254181.278236.984224.959294.011282.862314.711383.481507.442690.33
Period201720182019202020212022202320242025TTM
Sales, quarterly96.67105.499106.664124.12133.537143.121150.571185.61211.03
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual34.61936.10743.50245.24746.96547.75449.1256.44457.51159.168
Period201720182019202020212022202320242025MRQ
Shares, quarterly55.09456.44456.74157.24957.38657.51158.35958.85859.168
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue690.33507.44383.48314.71282.86294.01224.96236.98181.28
Cost of Goods Sold Incl. D&A130.29114.2396.4178.0071.4069.0594.1440.4125.07
Gross Profit560.04393.22287.07236.72211.46224.96130.82196.57156.20
Selling, General and Administrative Excl. Other621.84479.95395.21360.42313.77277.83254.37221.82169.21
Research and Development187.19150.61136.43138.77123.27101.0085.3968.3149.68
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-61.80-86.73-108.14-123.70-102.31-52.87-123.55-25.25-13.00
Interest Expense4.824.6328.0513.6313.7213.3714.122.560.00
Unusual Expense114.37112.8714.235.00-20.00-20.000.0025.050.00
Net Income Before Taxes-174.51-193.04-145.60-133.73-98.43-49.27-132.31-50.04-12.37
Income Taxes-4.72-5.350.770.930.770.33-11.97-65.460.58
Consolidated Net Income-169.80-187.69-146.37-134.66-99.19-49.59-120.3515.42-12.95
Net Income From Continuing Operations-169.80-187.69-146.37-134.66-99.19-49.59-120.3515.42-12.95
Net Income-169.80-187.69-146.37-134.66-99.19-49.59-120.3515.42-12.95
EPS (Recurring)-1.47-1.90-2.59-2.71-2.39-1.37-2.700.80-0.37
EPS (Basic, Before Extraordinaries)-2.94-3.28-2.77-2.78-2.09-1.07-2.700.41-0.37
EPS (Diluted)-2.94-3.28-2.77-2.78-2.09-1.07-2.700.37-0.37
EBITDA-15.51-44.39-68.22-85.72-66.37-18.45-88.94-15.38-6.74
Non-Operating Income (Expense)6.4611.194.828.61-2.40-3.025.352.820.63
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense70.3154.6230.2138.2339.0617.8539.8034.8815.20
Price To Earnings Ratio-------204.16-
Price To Sales Ratio14.5512.7320.6312.237.337.0214.899.4610.94
Gross Margin81.1377.4974.8675.2274.7676.5258.1582.9586.17
Operating Margin-8.95-17.09-28.20-39.31-36.17-17.98-54.92-10.65-7.17
Net Margin-24.60-36.99-38.17-42.79-35.07-16.87-53.506.51-7.14
Shares Outstanding59.1757.5156.4449.1247.7546.9745.2543.5036.11
Market Capitalization13,981.7213,981.728,267.303,879.082,083.682,083.803,383.802,359.812,023.69

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue211.03185.61150.57143.12133.54124.12106.66105.50
Cost of Goods Sold Incl. D&A31.1634.0233.3431.7728.8326.9024.3228.64
Gross Profit179.87151.59117.23111.35104.7197.2282.3576.86
Selling, General and Administrative Excl. Other179.04167.36137.09138.35121.07119.91103.03105.53
Research and Development48.0951.3044.1543.6538.0736.5432.3536.53
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income0.83-15.77-19.86-27.00-16.36-22.69-20.68-28.67
Interest Expense1.091.461.121.151.181.151.161.57
Unusual Expense0.001.500.00112.870.000.000.000.00
Net Income Before Taxes2.32-17.72-19.30-139.82-16.00-19.41-17.82-33.69
Income Taxes0.300.660.48-6.160.230.250.33-0.11
Consolidated Net Income2.02-18.38-19.78-133.66-16.23-19.66-18.15-33.58
Net Income From Continuing Operations2.02-18.38-19.78-133.66-16.23-19.66-18.15-33.58
Net Income2.02-18.38-19.78-133.66-16.23-19.66-18.15-33.58
EPS (Recurring)0.03-0.29-0.34-0.95-0.28-0.34-0.32-0.60
EPS (Basic, Before Extraordinaries)0.03-0.31-0.34-2.32-0.28-0.34-0.32-0.60
EPS (Diluted)0.03-0.31-0.34-2.32-0.28-0.34-0.32-0.60
EBITDA10.86-5.62-6.97-13.77-6.18-13.06-11.37-15.65
Non-Operating Income (Expense)2.581.001.681.201.544.434.02-3.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.0422.8015.1218.3411.7814.2410.2610.51
Price To Sales Ratio14.5513.4111.3312.809.9613.6513.7821.73
Gross Margin85.2381.6777.8677.8078.4178.3377.2072.86
Operating Margin0.39-8.49-13.19-18.87-12.26-18.28-19.39-27.17
Net Margin0.96-9.90-13.14-93.39-12.15-15.84-17.01-31.83
Shares Outstanding59.1758.8658.3657.5157.3957.2556.7456.44
Market Capitalization13,981.728,208.656,252.766,484.954,676.895,902.045,567.368,267.30

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments278.76318.92295.43352.69414.05404.37173.98140.49119.01
Short Term Receivables108.6160.7439.8536.0733.4436.0638.4218.6716.66
Inventories63.5657.6841.9937.8423.0115.8142.5813.2811.22
Other Current Assets24.0512.4618.1917.2515.6313.217.904.122.57
Total Current Assets474.98449.79395.46443.86486.13469.44262.88176.57149.46
Net Property, Plant & Equipment184.18169.94174.54166.83146.1395.4691.8119.1511.79
Total Investments and Advances23.3819.475.867.089.429.579.338.780.00
Intangible Assets208.63329.58349.09374.00398.92423.83448.740.003.15
Deferred Tax Assets36.8961.3966.5271.7879.13-0.000.210.23
Other Assets2.325.9715.4710.619.117.215.652.261.20
Total Assets930.371,036.151,006.941,074.171,128.831,005.50818.40206.97165.84
Short Term Debt Incl. Current Port. of LT Debt2.672.471.310.431.011.192.400.000.00
Accounts Payable24.6213.0313.4414.407.334.375.786.296.24
Other Current Liabilities73.9859.6259.2757.5355.0244.1549.5224.0820.54
Total Current Liabilities101.2875.1274.0172.3663.3649.7057.7030.3626.79
Long Term Debt103.88103.40383.74382.48382.38270.8172.630.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities37.3368.3273.6779.0586.4510.519.63--
Other Liabilities31.7422.3713.7510.289.497.035.172.750.85
Total Liabilities274.22269.22545.17544.16541.68338.05145.1333.1127.63
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity656.15766.93461.77530.00587.15667.45673.27173.86138.20
Total Shareholders Equity656.15766.93461.77530.00587.15667.45673.27173.86138.20
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity656.15766.93461.77530.00587.15667.45673.27173.86138.20
Total Liabilities & Stockholders Equity930.371,036.151,006.941,074.171,128.831,005.50818.40206.97165.84
Book Value Per Share11.4113.599.4011.1012.5014.7515.484.823.99
Tangible Book Value Per Share7.787.752.293.274.015.385.164.823.90
Full-Time Employees1,094995907783727653600437387
Price to Book Ratio19.4812.368.113.803.555.103.5211.676.71
Return on Assets-19.09-14.33-12.94-9.01-4.65-13.203.01-6.95-0.06
Return on Equity-26.38-23.83-27.16-17.76-7.91-17.953.64-8.30-0.07
Return on Invested Capital-24.70-16.82-15.93-10.87-5.12-12.832.07-7.45-0.07
Quick Ratio4.065.224.785.617.319.133.825.385.16
Current Ratio4.695.995.346.137.679.454.565.815.58

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-169.80-187.69-146.37-134.66-99.19-49.59-120.3515.42-12.95
Depreciation46.2842.3439.9237.9835.9534.4234.619.866.26
Other Funds (Non Cash)222.05185.0684.8249.1843.6737.3378.1545.1229.13
Funds from Operations92.0533.23-21.84-47.62-19.6421.13-19.764.1022.44
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-44.34-48.02-39.47-10.13-13.453.58-3.22-4.47-3.58
Cash from Operating Activities47.71-14.79-61.32-57.76-33.0824.71-22.99-0.3718.86
Capital Expenditures-28.30-24.27-6.30-20.25-30.27-47.78-6.93-4.72-10.31
Net Assets From Acquisitions0.00-12.440.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses-0.000.040.000.150.000.0049.65-
Purchase or Sale of Investments0.74-35.3557.2437.5175.90-8.37-196.310.11-14.85
Purchase of Investments-159.56-232.29-189.96-265.59-59.26-215.28-301.00-80.39-93.70
Sale Or Maturity of Investments160.30196.94247.20303.10135.16206.92104.7080.4978.85
Other Uses11.32-5.55-3.15-3.17-1.01-2.08-1.82-1.61-1.24
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-16.23-77.6147.8314.1044.78-58.23-205.0643.43-26.40
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock44.3221.1446.7619.039.2130.9424.2218.4521.58
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock44.3221.1446.7619.039.2130.9424.2218.4521.58
Proceedsfrom Stock Options7.817.697.426.285.634.824.033.39-0.59
Issuance or Reduction of Debt, Net-1.29-1.1251.34-0.71-0.53-0.66242.21-22.500.00
Change in Long Term Debt-1.29-1.1251.34-0.71-0.53-0.66242.21-22.500.00
Issuance of Long Term Debt0.000.0053.220.000.000.00287.500.000.00
Reduction of Long Term Debt-1.29-1.12-1.88-0.71-0.53-0.66-45.29-22.500.00
Net Financing Active Other Cash Flow-9.15-8.13-6.56-3.27-2.438.98-3.89-5.600.00
Other Financing Activities Uses-9.15-8.13-6.56-3.27-2.73-3.69-3.89-5.600.00
Cash from Financing Activities33.8711.8991.5415.046.2539.26262.54-9.6421.58
Exchange Rate Effect-1.990.80-3.021.34-1.47-1.77-0.09-0.250.05
Net Change in Cash63.36-79.7175.04-27.2816.483.9634.4133.1614.09
Free Cash Flow19.41-39.06-67.62-78.01-63.35-23.08-29.92-5.098.55
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow517.58-------232.05
Deferred Taxes & Investment Tax Credit--6.49-0.22-0.12-0.05-1.03-12.18-66.310.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments336.70286.23276.69278.76273.71274.79
Short Term Receivables150.00138.90119.69108.6198.6882.98
Inventories61.0359.3162.3863.5663.8664.62
Other Current Assets31.9131.3526.9924.0518.5113.67
Total Current Assets579.65515.78485.75474.98454.77436.06
Net Property, Plant & Equipment180.46181.58182.26184.18182.49184.41
Total Investments and Advances27.1426.5423.6623.3822.5721.04
Intangible Assets187.97193.86199.74208.63330.85337.20
Deferred Tax Assets---36.89--
Other Assets4.312.761.922.328.708.24
Total Assets979.53920.52893.33930.37999.38986.96
Short Term Debt Incl. Current Port. of LT Debt0.000.000.002.670.000.00
Accounts Payable24.4119.1419.1524.6219.8813.68
Other Current Liabilities102.3283.1970.2673.9867.6365.45
Total Current Liabilities126.73102.3389.42101.2887.5279.14
Long Term Debt101.98102.84103.06103.88104.31105.02
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.440.440.4437.336.926.91
Other Liabilities33.1032.4329.4931.7431.0830.78
Total Liabilities262.25238.03222.40274.22229.84221.85
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity717.27682.49670.93656.15769.54765.11
Total Shareholders Equity717.27682.49670.93656.15769.54765.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity717.27682.49670.93656.15769.54765.11
Total Liabilities & Stockholders Equity979.53920.52893.33930.37999.38986.96
Book Value Per Share12.1211.6011.5011.4113.4113.36
Tangible Book Value Per Share8.958.308.077.787.647.47
Full-Time Employees---1,094--
Price to Book Ratio19.4812.169.448.426.107.67
Return on Assets-17.16-19.72-20.36-19.09-9.10-9.73
Return on Equity-22.84-25.98-26.39-26.38-12.19-12.98
Return on Invested Capital0.25-2.34-2.56-17.59-1.86-2.26
Quick Ratio4.094.464.734.064.474.69
Current Ratio4.575.045.434.695.205.51

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income2.02-18.38-19.78-133.66-16.23-19.66
Depreciation10.0310.1412.8813.2310.199.62
Other Funds (Non Cash)33.7034.2518.21135.8811.6024.07
Funds from Operations45.7526.0211.318.975.5714.03
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-7.18-11.19-23.83-2.13-15.66-7.05
Cash from Operating Activities38.5714.82-12.536.84-10.096.98
Capital Expenditures-2.08-2.74-3.96-19.52-1.64-1.18
Net Assets From Acquisitions0.000.000.000.000.00-12.44
Sale of Fixed Assets and Businesses-0.000.000.000.000.00
Purchase or Sale of Investments-2.860.5615.22-12.18-0.8211.51
Purchase of Investments-52.55-35.49-31.35-40.16-75.37-42.02
Sale Or Maturity of Investments49.6936.0546.5827.9874.5453.53
Other Uses-0.60-3.13-0.7615.81-1.53-18.68
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-5.54-5.3110.50-15.89-3.99-20.78
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock15.594.1021.712.926.214.97
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock15.594.1021.712.926.214.97
Proceedsfrom Stock Options5.430.002.380.004.720.00
Issuance or Reduction of Debt, Net-0.35-0.34-0.30-0.30-0.29-0.28
Change in Long Term Debt-0.35-0.34-0.30-0.30-0.29-0.28
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.35-0.34-0.30-0.30-0.29-0.28
Net Financing Active Other Cash Flow-0.55-2.77-5.64-0.19-0.65-2.45
Other Financing Activities Uses-0.55-2.77-5.64-0.19-0.65-2.45
Cash from Financing Activities14.690.9915.772.435.262.25
Exchange Rate Effect0.13-0.99-0.31-0.816.25-2.78
Net Change in Cash47.849.5213.44-7.43-2.57-14.34
Free Cash Flow36.4912.09-16.48-12.68-11.725.80
Price to Free Cash Flow517.58-----

Revenue breakdown

Corneal Health2024: 80.21M 2025: 86.37M
Glaucoma2024: 303.28M 2025: 421.07M
Non-US2024: 113.39M 2025: 132.40M
United States2024: 270.09M 2025: 375.04M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.89%4.5M56.9M950.48K
2026-10-157.67%4.3M56.6M851.68K
2026-09-306.80%3.9M56.6M796.92K
2026-09-157.36%4.2M56.6M802.96K
2026-08-316.75%3.8M56.6M881.86K
2026-08-146.98%4.0M56.6M1.03M
2026-07-316.40%3.6M56.6M1.03M
2026-07-158.34%4.7M56.4M994.97K
2026-06-307.89%4.4M56.4M975.52K
2026-06-157.41%4.2M56.4M934.08K
2026-05-295.53%3.1M56.4M850.87K
2026-05-155.86%3.3M56.4M763.09K
2026-04-305.18%2.9M56.1M745.10K
2026-04-155.83%3.2M55.5M777.64K
2026-03-315.59%3.1M55.5M798.32K
2026-03-134.82%2.7M55.5M780.95K
2026-02-275.18%2.9M55.5M769.98K
2026-02-134.87%2.7M55.5M801.54K
2026-01-304.51%2.5M55.0M904.16K
2026-01-154.05%2.2M55.0M1.10M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1000.000.000.00-0.000.00---
call1050.000.000.00-0.000.00---
call1100.000.000.00-0.000.00---
call1150.000.000.00-0.000.00---
call1200.000.000.00-0.000.00---
call1250.000.0050.00-1.000.00---
call1300.000.000.00-0.000.00---
call1350.000.000.00-0.000.00---
call1400.000.0026.64-1.000.00---
call1450.000.0080.20-1.000.00---
call1500.000.0022.90-4.000.00---
call1550.000.0072.90-5.000.00---
call1600.000.0067.90-8.000.00---
call1650.000.0020.96-10.000.00---
call1700.000.0067.90-42.000.00---
call1750.000.0059.50-44.000.00---
call1800.000.0060.78-2760.00---
call1850.000.0054.20-31.000.00---
call1900.000.0012.10-27.000.00---
call1950.000.0043.20-25.000.00---
call2000.000.0025.80-3060.00---
call2100.000.0033.05-25.000.00---
call2200.000.0018.70-38.000.00---
call2300.000.0010.09-19.000.00---
call2400.000.007.75-19.000.00---
call2500.000.004.02-2300.00---
call2600.000.002.20-1700.00---
call2700.000.001.50-83.000.00---
call2800.000.002.00-12.000.00---
call2900.000.000.00-0.000.00---
call3000.000.000.00-1.000.00---
call3100.000.000.01-2.000.00---
call3200.000.000.00-0.000.00---
call3300.000.000.00-0.000.00---
call3400.000.000.00-0.000.00---
call3500.000.000.00-0.000.00---
call3600.000.000.00-0.000.00---
put1000.000.000.01-4.000.00---
put1050.000.001.00-7.000.00---
put1100.000.001.10-3.000.00---
put1150.000.002.35-7.000.00---
put1200.000.000.01-4.000.00---
put1250.000.000.08-12.000.00---
put1300.000.001.07-13.000.00---
put1350.000.002.10-30.000.00---
put1400.000.000.05-1010.00---
put1450.000.000.14-36.000.00---
put1500.000.001.09-2,0410.00---
put1550.000.006.10-1270.00---
put1600.000.000.31-1180.00---
put1650.000.000.05-2,1110.00---
put1700.000.009.75-8550.00---
put1750.000.000.05-2950.00---
put1800.000.000.80-1770.00---
put1850.000.001.20-59.000.00---
put1900.000.002.00-46.000.00---
put1950.000.000.95-11.000.00---
put2000.000.001.00-1170.00---
put2100.000.002.30-90.000.00---
put2200.000.007.60-1510.00---
put2300.000.006.00-2,4060.00---
put2400.000.0010.20-40.000.00---
put2500.000.0030.30-1030.00---
put2600.000.0014.00-14.000.00---
put2700.000.0039.40-26.000.00---
put2800.000.000.00-0.000.00---
put2900.000.0060.50-0.000.00---
put3000.000.0068.50-0.000.00---
put3100.000.000.00-0.000.00---
put3200.000.000.00-0.000.00---
put3300.000.000.00-0.000.00---
put3400.000.000.00-0.000.00---
put3500.000.000.00-0.000.00---
put3600.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-068-KCurrent report2026-11-06SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-04144Filing for proposed sale of securities under Rule 144.SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2024-04-09SEC
2026-10-30144Filing for proposed sale of securities under Rule 144.SEC
2026-10-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-25144Filing for proposed sale of securities under Rule 144.SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-08-28SEC
2026-08-28144Filing for proposed sale of securities under Rule 144.SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-07-31144Filing for proposed sale of securities under Rule 144.SEC
2026-07-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-16144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100632.50K1
2026-100010.87M2
2026-0900492.36K2
2026-080017.35M4
2026-07004.84M5
2026-0600200.86K1
2026-05004.43M4
2026-04001.65M2
2026-0300590.44K4
2026-02001.76M1
2026-010035.44M5
2025-1200536.35K1
2025-11001.77M2

Institutional holders

Manager% owned
BlackRock, Inc.16.24%
Jupiter Topco LLC8.28%
VANGUARD PORTFOLIO MANAGEMENT LLC5.66%
PRIMECAP MANAGEMENT CO/CA/5.18%
FMR LLC4.86%
VANGUARD CAPITAL MANAGEMENT LLC4.34%
STATE STREET CORP3.94%
MILLENNIUM MANAGEMENT LLC2.69%
Holocene Advisors, LP2.58%
GEODE CAPITAL MANAGEMENT, LLC2.46%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF6.02%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF2.52%
VANGUARD CAPITAL OPPORTUNITY FUND2.52%
VANGUARD SMALL-CAP INDEX FUND2.18%
Janus Henderson Triton Fund1.80%
PRIMECAP Odyssey Aggressive Growth Fund1.71%
SMALLCAP World Fund Inc1.68%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.26%
Janus Henderson Enterprise Fund1.21%

OakChart. GKOS. Cached 15 minutes.